For example, treatment of human breast cancer T47D cells with the MEK inhibitor U0126 in combination with the phosphoinositide 3-kinase/Akt inhibitor wortmannin synergistically suppressed EGF-induced ERK activation relative to treatment with U0126 alone [45]. The gene discussed is MAPK1; the disease is breast cancer.